1. S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (27th September 2022) Authors: Van Vollenhoven, R; Pike, M; Merrill, JT; Morand, E; Werth, VP; Hobar, C; Delev, N; Shah, V; Sharkey, B; Wegman, T; Catlett, I; Banerjee, S; Singhal, S Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗